Stock Scorer

Astrazeneca PLC (AZN.L)

Astrazeneca PLC reported revenue of 58.7B USD for the year ending 31 December 2025, up 8.6% from 54.1B a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue 2025 · ending 31 December 2025 58.7B +8.6%
Gross Profit 2025 · ending 31 December 2025 48.1B +9.7%
Operating Income 2025 · ending 31 December 2025 13.7B +37.4%
Net Income 2025 · ending 31 December 2025 10.2B +45.3%
Cost of Revenue 2025 · ending 31 December 2025 10.6B +4.2%
Operating Cash Flow 2025 · ending 31 December 2025 14.6B +22.9%
Free Cash Flow 2025 · ending 31 December 2025 11.8B +18.4%
Shares Outstanding 2025 · ending 31 December 2025 1.6B +0.0%
EPS 2025 · ending 31 December 2025 6.54 +45.3%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 58.7B13.7B10.2B11.8B
20242024-12-31 54.1B10B7B9.9B
20232023-12-31 45.8B8.2B6B9B
20222022-12-31 44.4B3.8B3.3B8.7B
20212021-12-31 37.4B1.1B115M4.9B
20202020-12-31 26.6B5.2B3.1B3.8B
20192019-12-31 24.4B2.9B1.2B2B

Every period

Revenue Annual

PeriodEndingRevenue
FY252025-12-3158.7B
FY242024-12-3154.1B
FY232023-12-3145.8B
FY222022-12-3144.4B
FY212021-12-3137.4B

Gross Profit Annual

PeriodEndingGross Profit
FY252025-12-3148.1B
FY242024-12-3143.9B
FY232023-12-3137.5B
FY222022-12-3132B
FY212021-12-3125B

Operating Income Annual

PeriodEndingOperating Income
FY252025-12-3113.7B
FY242024-12-3110B
FY232023-12-318.2B
FY222022-12-313.8B
FY212021-12-311.1B

Net Income Annual

PeriodEndingNet Income
FY252025-12-3110.2B
FY242024-12-317B
FY232023-12-316B
FY222022-12-313.3B
FY212021-12-31115M

Cost of Revenue Annual

PeriodEndingCost of Revenue
FY252025-12-3110.6B
FY242024-12-3110.2B
FY232023-12-318.3B
FY222022-12-3112.4B
FY212021-12-3112.4B

Operating Cash Flow Annual

PeriodEndingOperating Cash Flow
FY252025-12-3114.6B
FY242024-12-3111.9B
FY232023-12-3110.3B
FY222022-12-319.8B
FY212021-12-316B

Free Cash Flow Annual

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
FY252025-12-3111.8B
FY242024-12-319.9B
FY232023-12-319B
FY222022-12-318.7B
FY212021-12-314.9B

Shares Outstanding Annual

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
FY252025-12-311.6B
FY242024-12-311.6B
FY232023-12-311.5B
FY222022-12-311.5B
FY212021-12-311.4B

EPS Annual

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
FY252025-12-316.54
FY242024-12-314.50
FY232023-12-313.81
FY222022-12-312.11
FY212021-12-310.08